139 related articles for article (PubMed ID: 36183501)
21. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.
Zhang W; Chen Y; Chen L; Guo R; Zhou G; Tang L; Mao Y; Li W; Liu X; Du X; Sun Y; Ma J
Medicine (Baltimore); 2015 May; 94(20):e845. PubMed ID: 25997061
[TBL] [Abstract][Full Text] [Related]
22. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
[TBL] [Abstract][Full Text] [Related]
23. Circulating Plasma Epstein-Barr Virus DNA Load During the Follow-up Periods Predicts Recurrence and Metastasis in Nasopharyngeal Carcinoma.
He SS; Wang Y; Yang YY; Niu SQ; Zhu MY; Lu LX; Chen Y
Cancer J; 2022 Mar-Apr 01; 28(2):85-92. PubMed ID: 35333490
[TBL] [Abstract][Full Text] [Related]
24. Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases.
Chen FP; Lin L; Liang JH; Tan SH; Ong EHW; Luo YS; Huang L; Sim AYL; Wang HT; Gao TS; Deng B; Zhou GQ; Kou J; Chua MLK; Sun Y
Ther Adv Med Oncol; 2021; 13():17588359211052417. PubMed ID: 34721672
[TBL] [Abstract][Full Text] [Related]
25. Association of Epstein-Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma.
Lu Y; Jiang Z; Lin H; Yang H; Chen X; Huang H
Future Oncol; 2022 Jul; 18(22):2441-2451. PubMed ID: 35678594
[No Abstract] [Full Text] [Related]
26. Detection of methylation status of Epstein-Barr virus DNA C promoter in the diagnosis of nasopharyngeal carcinoma.
Zheng XH; Wang RZ; Li XZ; Zhou T; Zhang JB; Zhang PF; Lu LX; Jia WH
Cancer Sci; 2020 Feb; 111(2):592-600. PubMed ID: 31834989
[TBL] [Abstract][Full Text] [Related]
27. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
28. Improved risk stratification of nasopharyngeal cancer by targeted sequencing of Epstein-Barr virus DNA in post-treatment plasma.
Chan DCT; Lam WKJ; Hui EP; Ma BBY; Chan CML; Lee VCT; Cheng SH; Gai W; Jiang P; Wong KCW; Mo F; Zee B; King AD; Le QT; Chan ATC; Chan KCA; Lo YMD
Ann Oncol; 2022 Aug; 33(8):794-803. PubMed ID: 35491007
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.
Alami IE; Gihbid A; Charoute H; Khaali W; Brahim SM; Tawfiq N; Cadi R; Belghmi K; El Mzibri M; Khyatti M
Pan Afr Med J; 2022; 41():6. PubMed ID: 35145598
[TBL] [Abstract][Full Text] [Related]
31. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
32. Genotypic Characterization of Epstein Barr Virus in Blood of Patients with Suspected Nasopharyngeal Carcinoma in Ghana.
Ayee R; Ofori MEO; Tagoe EA; Languon S; Searyoh K; Armooh L; Bilson-Amoah E; Baidoo K; Kitcher E; Wright E; Quaye O
Viruses; 2020 Jul; 12(7):. PubMed ID: 32708700
[TBL] [Abstract][Full Text] [Related]
33. Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
Lin C; Lin K; Zhang B; Su Y; Guo Q; Lu T; Xu Y; Lin S; Zong J; Pan J
Oncologist; 2022 Apr; 27(4):e340-e349. PubMed ID: 35380720
[TBL] [Abstract][Full Text] [Related]
34. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
[TBL] [Abstract][Full Text] [Related]
35. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
36. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
[TBL] [Abstract][Full Text] [Related]
37. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of hepatitis B viral infection in Epstein-Barr virus-associated nasopharyngeal carcinoma.
Xu T; Huang Z; Deng Y; Wang S; Su B; Wei W; Wang D; Jiang J; Li A; Zhang G; Yang H; Claret FX; Hu W
J Clin Virol; 2015 Mar; 64():64-71. PubMed ID: 25728081
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
